Bayer builds on NAT (nucleic acid diagnostic) with $61.4 million Visible Genetics deal
This article was originally published in Clinica
Executive Summary
Bayer Diagnostics is to significantly expand its nucleic acid diagnostic (NAT) business with its planned $61.4m acquisition of tiny pharmacogenomics company Visible Genetics. In the cash deal, Bayer is offering $1.50 per Visible Genetics' share and its series A preferred shares at par plus accrued dividends.